Osteosarcoma (OS) is a quintessential “cold tumor,” and outcomes for patients with metastatic or recurrent disease have remained poor for decades. The failure of immune checkpoint inhibitors (ICIs) in OS reflects a multilayered immunosuppressive architecture rather than a single dominant lesion. This review deconstructs three principal barriers within that architecture: (1) physical T-cell exclusion driven by a dense fibrotic stroma and aberrant vasculature; (2) a myeloid-dominant suppressive network enriched for Tumor-Associated Macrophages (TAMs) and Myeloid-Derived Suppressor Cells (MDSCs); and (3) Antigen Presentation Machinery (APM) defects, most commonly loss of MHC-I/B2M. In parallel, the primary tumor actively engineers the pulmonary environment through exosomes and Neutrophil Extracellular Traps (NETs), establishing a Pre-metastatic Niche (PMN) that facilitates lung metastasis. Integrating evidence from single-cell and spatial omics, multi-modal imaging (radiomics, digital pathology), and liquid biopsy (ctDNA-minimal residual disease MRD), this review translates biological “decoding” of the OS microenvironment into a hypothesis-generating operational framework. We propose an “OS-TME Subtyping V1.0” model in which subtypes are treated as dynamic, dominant-barrier system states rather than fixed biological classes. In its current conceptual form, state assignment is envisioned as a semi-structured, rule-based process using concordant signals from pathology/spatial readouts, imaging surrogates, and ctDNA/immune context; mixed or discordant cases are intentionally retained as indeterminate states for reassessment rather than forcibly classified. On this basis, we outline a sequential “De-suppression → Priming → Checkpoint” logic tailored to different barrier-dominant states. For myeloid-dominant states, we prioritize myeloid reprogramming (e.g., CSF1R/CCR2-axis targeting) combined with immunogenic priming. For dense fibrotic stroma/angio-abnormal states, we emphasize up-front vessel/stroma remodeling before checkpoint therapy. For APM-defective states, we discuss MHC-independent approaches targeting B7-H3 or GD2 (e.g., CAR-T/NK cells, antibody-drug conjugates), while explicitly acknowledging target heterogeneity, trafficking barriers, and on-target/off-tumor risk. To narrow the translational gap, we further outline a perioperative “Window of Opportunity” (WoO) trial prototype and a conceptual “Cold-to-Hot Readiness Index (RI)” that integrates dynamic imaging, pathology, and MRD monitoring. The RI is presented only as an illustrative, hypothesis-generating summary variable intended for retrospective stratification, simulation modeling, or biomarker-guided early-phase trial design, rather than near-term routine clinical decision-making. Together, these elements define a theoretical blueprint for iterative state assessment and adaptive therapeutic sequencing in osteosarcoma. ICI resistance in Osteosarcoma (OS) originates from a triad of barriers—“dense fibrotic stroma/vasculature,” “myeloid suppression,” and “APM defects”—and is compounded by active shaping of the pulmonary pre-metastatic niche. We propose a conceptual “OS-TME V1.0” framework that treats subtypes as dynamic dominant-barrier states and uses a minimal viable panel of imaging, pathology/spatial readouts, and ctDNA to support hypothesis-generating stratification. A sequential “De-suppression → Priming → Checkpoint” logic is discussed in an evidence-tiered manner, distinguishing OS-supported pathways from cross-tumor extrapolations and matching APM-defective tumors to MHC-independent strategies only with appropriate caution about heterogeneity and toxicity. We outline a perioperative “Window of Opportunity” (WoO) prototype and a conceptual “Cold-to-Hot Readiness Index (RI)” for short-interval reassessment and adaptive sequencing; both are proposed as exploratory research tools rather than validated clinical algorithms.
Yang et al. (Wed,) studied this question.